CDR132L

Phase 2Small molecule

CCardior Pharmaceuticals GmbH

CDR132L is one of 52 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureRecruiting

Left Ventricular HypertrophyRecruiting

Heart FailurePhase 2

Recruiting

Left Ventricular HypertrophyPhase 2

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Activase

Zemplar

Adriamycin

Savaysa

CDR132L

CCardior Pharmaceuticals GmbH

Phase 2

2 10

Xifaxan

SSalix

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Heart Failure

NCT07656454

Q1 2028

Phase 2Recruiting

Left Ventricular Hypertrophy

NCT06979375

Q3 2028

Phase 2Recruiting

Heart Failure

NCT06979362

Clinical

Trials by Indication[1]

Heart Failure2 trials

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06979362·200 enrolled

A Bioavailability Study Comparing the Pharmacokinetics of CDR132L Following Subcutaneous and Intravenous Administration in Healthy Participants

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07656454·32 enrolled

Left Ventricular Hypertrophy1 trial

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06979375·200 enrolled

ESS1 trial

Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

Completed·CCardior Pharmaceuticals GmbH·Phase 1·NCT04045405·28 enrolled

Myocardial Infarction, Acute1 trial

Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction

Completed·CCardior Pharmaceuticals GmbH·Phase 2·NCT05350969·294 enrolled

Heart Failure With Preserved Ejection Fraction1 trial

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

Withdrawn·CCardior Pharmaceuticals GmbH·Phase 2·NCT05953831

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CDR132L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDR132L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDR132L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cardior Pharmaceuticals GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCardior Pharmaceuticals GmbH

CDR132L

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q3 2028

Trials by Indication[1]

Heart Failure2 trials

Left Ventricular Hypertrophy1 trial

ESS1 trial

Myocardial Infarction, Acute1 trial

Heart Failure With Preserved Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News